KLRA Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

23.823

Open

23.300

VWAP

21.99

Vol

1.65M

Mkt Cap

2.88B

Low

19.900

Amount

36.24M

EV/EBITDA(TTM)

Total Shares

129.57M

EV/OCF(TTM)

P/S(TTM)

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.

Events Timeline

(ET)

2026-07-07

10:00:00

Kailera Therapeutics Reports Positive Phase 3 Results for HRS-7535

2026-06-29 (ET)

2026-06-29

08:00:00

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

2026-05-11 (ET)

2026-05-11

11:30:00

Mobia Medical, Odyssey Therapeutics and Others Go Public This Week

2026-04-22 (ET)

2026-04-22

08:20:00

PMV Pharmaceuticals Board Transition, Laurie Stelzer Appointed New Chair

News

9.5

07-07seekingalpha

PinnedKailera Therapeutics Shares Drop Over 10% After Trial Data

8.5

07-07seekingalpha

Kalohexis Files for Potential U.S. IPO

2.0

07-07Newsfilter

Kailera's HRS-7535 Clinical Trials Show Positive Results

8.5

07-02Fool

Pfizer Eyes Kailera Acquisition to Expand Weight Loss Portfolio

8.5

06-18Yahoo Finance

Kardigan's Shares Rise 1.6% in Successful Nasdaq Debut

8.5

06-16NASDAQ.COM

Three Innovative Biotechs with Promising Prospects

0 Analyst Rating

Wall Street analysts forecast KLRA stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Evercore ISI

Umer Raffat

initiated

AI Analysis

2026-05-12

Reason

Evercore ISI

Umer Raffat

Price Target

AI Analysis

2026-05-12

initiated

Reason

Evercore ISI analyst Umer Raffat initiated coverage of Kailera Therapeutics with an Outperform rating and no price target. Kailera is \"making waves in the GIP-GLP space with impressive early-stage data,\" says the analyst, who notes that a head-to-head trial against semaglutide is underway in China, with data expected in early 2027. Initial expectations suggest Kailera could outperform semaglutide by at least 6 percentage points in weight loss, though \"the full potential of oral formulations may take time to unfold,\" the analyst added.

Leerink

Outperform

initiated

$36

2026-05-12

Reason

Leerink

Price Target

$36

2026-05-12

initiated

Outperform

Reason

Leerink initiated coverage of Kailera Therapeutics (KLRA) with an Outperform rating and $36 price target. The firm believes the company's obesity candidate offer key advantages relative to competing assets, including potential injectable ribupatide efficacy greater than Eli Lilly's (LLY) tirzepatide and oral ribupatide advantages over Novo Nordisk's (NVO) oral Wegovy and Lilly's Foundayo. The company is also leveraging high-quality R&D from China's number one biopharma company, Henguri, Leerink says, adding that Kailera has exceptional leadership with proven track records.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KLRA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Kailera Therapeutics Inc (KLRA.O) is 0.00, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Kailera Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

Current PE

0.00

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

Current PS

0.00

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding KLRA

Trading Trends

People Also Watch

Frequently Asked Questions

What is Kailera Therapeutics Inc (KLRA) stock price today?

The current price of KLRA is 22.24 USD — it has decreased -4.55

What is Kailera Therapeutics Inc (KLRA)'s business?

What is the price predicton of KLRA Stock?

Wall Street analysts forecast KLRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLRA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.